News
CDXS
1.410
+3.68%
0.050
Weekly Report: what happened at CDXS last week (0928-1002)?
Weekly Report · 5d ago
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
NASDAQ · 10/02 16:13
Codexis partners with siRNA drug innovator for enzymatic oligonucleotide synthesis
Seeking Alpha · 09/28 11:02
Codexis Shares Gain on Agreement With Undisclosed Drug Innovator
Dow Jones · 09/28 11:00
Weekly Report: what happened at CDXS last week (0921-0925)?
Weekly Report · 09/28 10:21
Codexis announces agreement with siRNA drug innovator
TipRanks · 09/28 10:20
Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing Platform
Benzinga · 09/28 10:03
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)
TipRanks · 09/23 08:50
Codexis (CDXS) Has a New Rating from Stephens
TipRanks · 09/22 12:56
Weekly Report: what happened at CDXS last week (0914-0918)?
Weekly Report · 09/21 10:21
Weekly Report: what happened at CDXS last week (0907-0911)?
Weekly Report · 09/14 10:26
Weekly Report: what happened at CDXS last week (0831-0904)?
Weekly Report · 09/07 10:19
Weekly Report: what happened at CDXS last week (0824-0828)?
Weekly Report · 08/31 10:27
Weekly Report: what happened at CDXS last week (0817-0821)?
Weekly Report · 08/24 10:28
Codexis Earnings Call: Margin Gains, Scale-Up Bets
TipRanks · 08/20 00:27
Codexis (CDXS) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/18 23:27
Codexis Is Maintained at Overweight by Piper Sandler
Dow Jones · 08/17 16:15
Codexis Price Target Cut to $8.00/Share From $9.00 by Piper Sandler
Dow Jones · 08/17 16:15
Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8
Benzinga · 08/17 16:05
Weekly Report: what happened at CDXS last week (0810-0814)?
Weekly Report · 08/17 10:29
More
Webull provides a variety of real-time CDXS stock news. You can receive the latest news about Codexis Inc through multiple platforms. This information may help you make smarter investment decisions.
About CDXS
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.